Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort.

Apicella, M

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort. [electronic resource] - Oncogene 03 2017 - 1200-1210 p. digital

Publication Type: Journal Article

1476-5594

10.1038/onc.2016.283 doi


Aged, 80 and over
Animals
Antineoplastic Combined Chemotherapy Protocols--pharmacology
Apoptosis--drug effects
Biomarkers, Tumor--genetics
Cell Proliferation--drug effects
Cetuximab--administration & dosage
Drug Resistance, Neoplasm--genetics
ErbB Receptors--antagonists & inhibitors
Esophageal Neoplasms--drug therapy
Esophagogastric Junction--drug effects
Gene Amplification
Humans
Lapatinib
Male
Mice
Mice, Inbred NOD
Mice, SCID
Phosphorylation
Proto-Oncogene Proteins c-met--antagonists & inhibitors
Quinazolines--administration & dosage
Signal Transduction
Stomach Neoplasms--drug therapy
Tumor Cells, Cultured
Xenograft Model Antitumor Assays